{"id":782545,"date":"2023-09-07T13:45:15","date_gmt":"2023-09-07T17:45:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\/"},"modified":"2023-09-07T13:45:15","modified_gmt":"2023-09-07T17:45:15","slug":"sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\/","title":{"rendered":"Sarepta TherapeuticsAnnounces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Sarepta Therapeutics<\/b><b>Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year<\/b><\/p>\n<p>\n\u2013 <b><i>Recipients include 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with Duchenne<\/i><\/b><\/p>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program for the 2023-2024 academic year. Of the 25 recipients, academic scholarships will be awarded to 20 individuals living with Duchenne muscular dystrophy and to five siblings of individuals living with Duchenne. Each recipient will receive a scholarship of up to $5,000.<\/p>\n<p>\n\u201cOn behalf of Sarepta and the selection committee, we are proud to announce the recipients of Route 79, The Duchenne Scholarship Program, for the 2023-2024 academic year. We continue to be impressed by each applicant and this year, we selected a total of 25 exceptionally bright students with passion for growth and a strong vision for their future,\u201d said Diane Berry, Sarepta\u2019s Executive Vice President and Chief Global Policy &amp; Advocacy Officer. \u201cEach student\u2019s essay demonstrated enthusiasm for their academic and life goals, a keen curiosity and admirable desire to learn, and the power of their own perseverance. We are honored to support this ambitious group of students and we wish them great success in their studies for the school year ahead.\u201d<\/p>\n<p>\nThe Route 79 program was created in 2018 to recognize exceptional individuals living with Duchenne as they pursue their post-secondary education. In 2022, Sarepta expanded the program to include siblings of individuals with Duchenne in recognition of the impact that a diagnosis of Duchenne may have on the entire family. Recipients of the scholarship are chosen by an independent selection committee composed of Duchenne community members, who consider each applicant\u2019s community involvement and personal essay. In addition to application review by the independent committee, submissions are de-identified for the voting panel with no indication of whether the candidate has received, or plans to receive, a Sarepta therapy.<\/p>\n<p><b><i>2023-2024 Route 79 Scholarship <\/i><i>Recipients<\/i><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nJohn &#8220;Jack&#8221; Becker, Embry-Riddle Aeronautical University, Daytona Beach<\/p>\n<\/li>\n<li>\nChristopher Cameron, Ball State University<\/p>\n<\/li>\n<li>\nJacob Colby, The Evergreen State College<\/p>\n<\/li>\n<li>\nKyle Cox, Texas A&amp;M University<\/p>\n<\/li>\n<li>\nAgranil Das, Stony Brook University<\/p>\n<\/li>\n<li>\nBlake Deakin, Arizona State University<\/p>\n<\/li>\n<li>\nCorbin Fanning, Texas A&amp;M University<\/p>\n<\/li>\n<li>\nAiden Fecteau, Eastern Connecticut State University<\/p>\n<\/li>\n<li>\nYuvaraj Gambhir, University of Pennsylvania<\/p>\n<\/li>\n<li>\nDeclan Hickey, Curry College<\/p>\n<\/li>\n<li>\nYujia Ji, The Ohio State University<\/p>\n<\/li>\n<li>\nElliott Johnson, Lebanon Valley College<\/p>\n<\/li>\n<li>\nRyan Lugo, State University of New York at New Paltz<\/p>\n<\/li>\n<li>\nBrian Madura, New Jersey Institute of Technology<\/p>\n<\/li>\n<li>\nJosh Pflueger, Texas Christian University<\/p>\n<\/li>\n<li>\nJasdeep Singh, Cleveland Institute of Art<\/p>\n<\/li>\n<li>\nVedant Singhania, San Jose State University<\/p>\n<\/li>\n<li>\nConnor Underwood, Pikes Peak State College<\/p>\n<\/li>\n<li>\nBraden Van Eperen, Union College<\/p>\n<\/li>\n<li>\nJack Wolf, University of Akron<\/p>\n<\/li>\n<\/ul>\n<p><b><i>2023-2024 Route 79 Sibling Scholarship <\/i><i>Recipients<\/i><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nHailey Baquiran, Dominican University of California<\/p>\n<\/li>\n<li>\nEllyn Beebe, University of Tennessee at Martin<\/p>\n<\/li>\n<li>\nIsabel Dreher, University of New Hampshire<\/p>\n<\/li>\n<li>\nLance Hains, West Chester University<\/p>\n<\/li>\n<li>\nGrace Lee, University of Colorado Boulder<\/p>\n<\/li>\n<\/ul>\n<p><b><i>About Route 79, The Duchenne Scholarship Program<\/i><\/b><\/p>\n<p>\nThe Route 79 program is designed to help students living with Duchenne and siblings of individuals living with Duchenne pursue their post-secondary educational goals. Scholarship recipients are chosen by an independent committee of Duchenne community members based on an applicant\u2019s community involvement, personal essay, and recommendation letter. The underlying cause of Duchenne is a difference in the gene coding for dystrophin. Dystrophin is an essential protein that plays a pivotal role in muscle structure, function and preservation. The numerical significance of the scholarship\u2019s name, Route 79, ties to the 79 exons of the dystrophin gene. For more information, visit sarepta.com\/route79.<\/p>\n<p><strong><i>About Sarepta Therapeutics<\/i><\/strong><\/p>\n<p>\nSarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sarepta.com&amp;esheet=53550401&amp;newsitemid=20230907578056&amp;lan=en-US&amp;anchor=www.sarepta.com&amp;index=1&amp;md5=ad0ce7408f547cf096d53761927ba0f7\">www.sarepta.com<\/a><b \/>or follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.twitter.com%2FSarepta&amp;esheet=53550401&amp;newsitemid=20230907578056&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=de610f5a75ae877e9d081950d78d7690\">Twitter<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsarepta-therapeutics&amp;esheet=53550401&amp;newsitemid=20230907578056&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=f2a4cb64a9f980b15ad127d6574d7659\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.instagram.com%2Fsareptatherapeutics%2F&amp;esheet=53550401&amp;newsitemid=20230907578056&amp;lan=en-US&amp;anchor=Instagram&amp;index=4&amp;md5=8556fdb41d779ffff082212f1c3d48d7\">Instagram<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FSarepta-Therapeutics-208950446535427%2F&amp;esheet=53550401&amp;newsitemid=20230907578056&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=9b79dafffaa659b995f863deb5ebdb56\">Facebook<\/a>.<\/p>\n<p><strong><i>Internet Posting of Information<\/i><\/strong><\/p>\n<p><i>We routinely post information that may be important to investors in the &#8216;For Investors&#8217; section of our website at <\/i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sarepta.com%2F&amp;esheet=53550401&amp;newsitemid=20230907578056&amp;lan=en-US&amp;anchor=www.sarepta.com&amp;index=6&amp;md5=a7a342df20386dda21ec33b9f6f73db6\"><i>www.sarepta.com<\/i><\/a><i>. We encourage investors and potential investors to consult our website regularly for important information about us.<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230907578056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230907578056\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230907578056\/en\/<\/a><\/span><\/p>\n<p><b><i>Investor:<br \/>\n<br \/><\/i><\/b>Ian Estepan, 617-274-4052<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:iestepan@sarepta.com\">iestepan@sarepta.com<\/a><\/p>\n<p><b><i>Media:<br \/>\n<br \/><\/i><\/b>Tracy Sorrentino, 617-301-8566<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:tsorrentino@sarepta.com\">tsorrentino@sarepta.com<\/a><\/p>\n<p>\nSierra Smith, 617-710-1385<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:sismith@sarepta.com\">sismith@sarepta.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research FDA Hispanic Biotechnology University Pharmaceutical Consumer Health Science Education<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230907578056\/en\/1815332\/3\/Sarepta_Corporate-_Stacked_Logo_%28Full_Color%29.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Sarepta TherapeuticsAnnounces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year \u2013 Recipients include 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with Duchenne CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program for the 2023-2024 academic year. Of the 25 recipients, academic scholarships will be awarded to 20 individuals living with Duchenne muscular dystrophy and to five siblings of individuals living with Duchenne. Each recipient will receive a scholarship of up to $5,000. \u201cOn behalf of Sarepta and the selection committee, we are proud to announce the recipients of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Sarepta TherapeuticsAnnounces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-782545","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sarepta TherapeuticsAnnounces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sarepta TherapeuticsAnnounces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Sarepta TherapeuticsAnnounces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year \u2013 Recipients include 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with Duchenne CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program for the 2023-2024 academic year. Of the 25 recipients, academic scholarships will be awarded to 20 individuals living with Duchenne muscular dystrophy and to five siblings of individuals living with Duchenne. Each recipient will receive a scholarship of up to $5,000. \u201cOn behalf of Sarepta and the selection committee, we are proud to announce the recipients of &hellip; Continue reading &quot;Sarepta TherapeuticsAnnounces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-07T17:45:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230907578056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sarepta TherapeuticsAnnounces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year\",\"datePublished\":\"2023-09-07T17:45:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\\\/\"},\"wordCount\":793,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230907578056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\\\/\",\"name\":\"Sarepta TherapeuticsAnnounces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230907578056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-09-07T17:45:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230907578056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230907578056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sarepta TherapeuticsAnnounces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sarepta TherapeuticsAnnounces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\/","og_locale":"en_US","og_type":"article","og_title":"Sarepta TherapeuticsAnnounces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year - Market Newsdesk","og_description":"Sarepta TherapeuticsAnnounces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year \u2013 Recipients include 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with Duchenne CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program for the 2023-2024 academic year. Of the 25 recipients, academic scholarships will be awarded to 20 individuals living with Duchenne muscular dystrophy and to five siblings of individuals living with Duchenne. Each recipient will receive a scholarship of up to $5,000. \u201cOn behalf of Sarepta and the selection committee, we are proud to announce the recipients of &hellip; Continue reading \"Sarepta TherapeuticsAnnounces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-07T17:45:15+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230907578056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sarepta TherapeuticsAnnounces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year","datePublished":"2023-09-07T17:45:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\/"},"wordCount":793,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230907578056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\/","name":"Sarepta TherapeuticsAnnounces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230907578056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-09-07T17:45:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230907578056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230907578056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeuticsannounces-recipients-of-the-6th-annual-route-79-the-duchenne-scholarship-program-for-the-2023-2024-academic-year\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sarepta TherapeuticsAnnounces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/782545","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=782545"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/782545\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=782545"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=782545"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=782545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}